Effectiveness of Motivational Interviewing in Patients With COPD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorZeynep Yildirim
About this trial
To determine the effect of motivational interviewing based on Pender's health promotion model on patient-reported outcomes in patients with COPD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Being over 18 years of age,
Volunteering to participate in the study,
Being literate,
Having GOLD Stage II and III COPD,
Disqualifiers
Having GOLD Stage I and IV COPD,
Having serious pulmonary and malignant disease,
Not being able to communicate in Turkish,
Being in an exacerbation period,
Trial design
Design model
Parallel
Treatments tested in this trial
Motivational interviewing based on Pender's health promotion model
Other interventionIn addition to routine nursing care, patients will be given a motivational interview intervention based on Pender's health promotion model. This intervention will be carried out in a total of 6 sessions, three face-to-face sessions and three online sessions planned individually for each patient. The interviews will last approximately 30-45 minutes. The first motivational interview will be held on the 1st day of the patient's admission to the clinic, the second motivational interview on the 4th day, and the third motivational interview on the 7th day. The face-to-face sessions will be conducted by the researcher in the hospital's education room and contact information will be obtained from the patients. The following three interviews will be held online with the patients once a week via the WhatsApp application. The patient will be contacted at least two days before the interviews, an appointment will be made, and the interview day and time will be determined.
Treatment groups
50 Participants
are divided into 2 treatment groupsGroup A: Motivational InterviewingExperimental treatment 1 intervention
Group B: Control GroupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Adapted Patient Reported Outcome Scale for Chronic Obstructive Pulmonary Disease
The Turkish validity and reliability study of the scale developed by Liu et al. in 2020 was conducted by Sazak and Orgun in 2023. The scale consists of 27 items in three dimensions. The dimensions are physical domain, environmental domain and psychological domain. The scale is a 5-point Likert type (Never 0, Almost never 1, A few times 2, Many times 3, Almost always 4). Item 13 should be reverse scored. Cronbach's Alpha reliability coefficient of the scale was determined as 0.954 for the overall scale, 0.945 for the physical domain sub-dimension, 0.862 for the psychological domain sub-dimension and 0.828 for the environmental sub-dimension.
Time frame
Up to 4 weeks2
Modified Medical Research Council (mMRC) Dyspnea Scale
The dyspnea scale, developed by Fletcher in 1952, was used to compare the dyspnea levels of individuals with lung disease and those without during activity. Later, the scale was developed by the British Medical Research Council (MRC) to evaluate the course of diseases. The scale, which is based on various physical activities to determine dyspnea, consists of 5 items and is scored between 0 and 4 points. The best point in terms of dyspnea on the scale is 0, while the worst is defined as 4 points.
Time frame
Up to 4 weeks3
COPD Assessment Test (CAT)
Developed by Jones et al. in 2009, the scale was validated in Turkish by Yorgancıoğlu et al. in 2012. CAT determines disease severity by evaluating symptoms such as cough, phlegm, shortness of breath, fatigue, and leaving home. The scores of the questions in the test range from "0-40". CAT assessment test score; 0-10 is considered "low impact", 11-20 is considered "moderate impact", 21-30 is considered "high impact", and 31-40 is considered "very high impact".
Time frame
Up to 4 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Zeynep Yildirim
Lead sponsor
Ataturk University
Sponsor institution
Source ClinicalTrials.gov